Conatus Pharmaceuticals (CNAT) Downgraded by ValuEngine to “Strong Sell”
ValuEngine downgraded shares of Conatus Pharmaceuticals (NASDAQ:CNAT) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday morning.
Several other analysts have also weighed in on CNAT. S&P Equity Research lifted their price objective on Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. Roth Capital started coverage on Conatus Pharmaceuticals in a report on Thursday, February 8th. They set a buy rating and a $20.00 price objective on the stock. SunTrust Banks decreased their price objective on Conatus Pharmaceuticals to $4.30 and set a buy rating on the stock in a report on Thursday, April 5th. HC Wainwright decreased their price objective on Conatus Pharmaceuticals from $17.00 to $15.00 and set a buy rating on the stock in a report on Thursday, April 5th. Finally, Oppenheimer set a $14.00 price objective on Conatus Pharmaceuticals and gave the stock a buy rating in a report on Thursday, April 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Conatus Pharmaceuticals presently has an average rating of Buy and a consensus target price of $12.00.
CNAT opened at $3.57 on Wednesday. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.47. Conatus Pharmaceuticals has a 12-month low of $3.44 and a 12-month high of $9.40.
Several large investors have recently made changes to their positions in CNAT. MPM Asset Management LLC grew its holdings in shares of Conatus Pharmaceuticals by 76.3% during the 4th quarter. MPM Asset Management LLC now owns 2,101,171 shares of the biotechnology company’s stock worth $9,707,000 after purchasing an additional 909,091 shares in the last quarter. State Street Corp acquired a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth approximately $2,092,000. Sterling Capital Management LLC bought a new position in shares of Conatus Pharmaceuticals during the 3rd quarter worth approximately $708,000. BlackRock Inc. lifted its position in shares of Conatus Pharmaceuticals by 6.2% during the 4th quarter. BlackRock Inc. now owns 1,593,395 shares of the biotechnology company’s stock worth $7,362,000 after buying an additional 93,015 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Conatus Pharmaceuticals by 26.2% during the 4th quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock worth $1,983,000 after buying an additional 89,179 shares during the period. 39.49% of the stock is currently owned by institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.